Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

B. L. Kasiske, Angelo M DeMattos, S. M. Flechner, L. Gallon, H. U. Meier-Kriesche, M. R. Weir, A. Wilkinson

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

The incidence, pathogenesis, consequences and treatment of mammalian target of rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic review of randomized controlled trials reporting cholesterol and triglycerides in mTOR versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or an increased prevalence of treatment with lipid-lowering agents. Approximately 60% of mTOR inhibitor-treated patients received lipid-lowering agents (2-fold higher than controls). There appeared to be little difference between dyslipidemias caused by sirolimus (14 trials) versus everolimus (3 trials). It was difficult to determine the extent to which declines in lipids over time posttransplant were due to lipid-lowering therapy, changes in doses and/or discontinuations of mTOR inhibitors. From the four trials that measured lipoproteins, it appeared that at least some of the increase in total cholesterol with mTOR inhibitors was due to increased low-density lipoprotein cholesterol. What direct or indirect effects mTOR inhibitors have on atherosclerotic cardiovascular disease in kidney transplant patients are unknown. However, in the absence of the necessary clinical trials, dyslipidemia should be managed, as it would be in nontransplant patients at high risk for cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)1384-1392
Number of pages9
JournalAmerican Journal of Transplantation
Volume8
Issue number7
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Sirolimus
Dyslipidemias
Kidney
Lipids
Triglycerides
Cardiovascular Diseases
Cholesterol
Transplant Recipients
Therapeutics
Immunosuppressive Agents
Hypercholesterolemia
LDL Cholesterol
Lipoproteins
Randomized Controlled Trials
Clinical Trials
Transplants
Incidence

Keywords

  • Cardiovascular risk factors
  • Clinical kidney transplantation
  • Clinical trials
  • Hypercholesterolemia
  • Hyperlipidemia
  • Hypertriglyceridemia
  • Systematic review

ASJC Scopus subject areas

  • Immunology

Cite this

Kasiske, B. L., DeMattos, A. M., Flechner, S. M., Gallon, L., Meier-Kriesche, H. U., Weir, M. R., & Wilkinson, A. (2008). Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. American Journal of Transplantation, 8(7), 1384-1392. https://doi.org/10.1111/j.1600-6143.2008.02272.x

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. / Kasiske, B. L.; DeMattos, Angelo M; Flechner, S. M.; Gallon, L.; Meier-Kriesche, H. U.; Weir, M. R.; Wilkinson, A.

In: American Journal of Transplantation, Vol. 8, No. 7, 07.2008, p. 1384-1392.

Research output: Contribution to journalArticle

Kasiske, BL, DeMattos, AM, Flechner, SM, Gallon, L, Meier-Kriesche, HU, Weir, MR & Wilkinson, A 2008, 'Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients', American Journal of Transplantation, vol. 8, no. 7, pp. 1384-1392. https://doi.org/10.1111/j.1600-6143.2008.02272.x
Kasiske, B. L. ; DeMattos, Angelo M ; Flechner, S. M. ; Gallon, L. ; Meier-Kriesche, H. U. ; Weir, M. R. ; Wilkinson, A. / Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. In: American Journal of Transplantation. 2008 ; Vol. 8, No. 7. pp. 1384-1392.
@article{012bf1665ded4628b4d1ec3d716d3f82,
title = "Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients",
abstract = "The incidence, pathogenesis, consequences and treatment of mammalian target of rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic review of randomized controlled trials reporting cholesterol and triglycerides in mTOR versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or an increased prevalence of treatment with lipid-lowering agents. Approximately 60{\%} of mTOR inhibitor-treated patients received lipid-lowering agents (2-fold higher than controls). There appeared to be little difference between dyslipidemias caused by sirolimus (14 trials) versus everolimus (3 trials). It was difficult to determine the extent to which declines in lipids over time posttransplant were due to lipid-lowering therapy, changes in doses and/or discontinuations of mTOR inhibitors. From the four trials that measured lipoproteins, it appeared that at least some of the increase in total cholesterol with mTOR inhibitors was due to increased low-density lipoprotein cholesterol. What direct or indirect effects mTOR inhibitors have on atherosclerotic cardiovascular disease in kidney transplant patients are unknown. However, in the absence of the necessary clinical trials, dyslipidemia should be managed, as it would be in nontransplant patients at high risk for cardiovascular disease.",
keywords = "Cardiovascular risk factors, Clinical kidney transplantation, Clinical trials, Hypercholesterolemia, Hyperlipidemia, Hypertriglyceridemia, Systematic review",
author = "Kasiske, {B. L.} and DeMattos, {Angelo M} and Flechner, {S. M.} and L. Gallon and Meier-Kriesche, {H. U.} and Weir, {M. R.} and A. Wilkinson",
year = "2008",
month = "7",
doi = "10.1111/j.1600-6143.2008.02272.x",
language = "English (US)",
volume = "8",
pages = "1384--1392",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients

AU - Kasiske, B. L.

AU - DeMattos, Angelo M

AU - Flechner, S. M.

AU - Gallon, L.

AU - Meier-Kriesche, H. U.

AU - Weir, M. R.

AU - Wilkinson, A.

PY - 2008/7

Y1 - 2008/7

N2 - The incidence, pathogenesis, consequences and treatment of mammalian target of rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic review of randomized controlled trials reporting cholesterol and triglycerides in mTOR versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or an increased prevalence of treatment with lipid-lowering agents. Approximately 60% of mTOR inhibitor-treated patients received lipid-lowering agents (2-fold higher than controls). There appeared to be little difference between dyslipidemias caused by sirolimus (14 trials) versus everolimus (3 trials). It was difficult to determine the extent to which declines in lipids over time posttransplant were due to lipid-lowering therapy, changes in doses and/or discontinuations of mTOR inhibitors. From the four trials that measured lipoproteins, it appeared that at least some of the increase in total cholesterol with mTOR inhibitors was due to increased low-density lipoprotein cholesterol. What direct or indirect effects mTOR inhibitors have on atherosclerotic cardiovascular disease in kidney transplant patients are unknown. However, in the absence of the necessary clinical trials, dyslipidemia should be managed, as it would be in nontransplant patients at high risk for cardiovascular disease.

AB - The incidence, pathogenesis, consequences and treatment of mammalian target of rapamycin (mTOR) inhibitor dyslipidemia are not well described. We conducted a systematic review of randomized controlled trials reporting cholesterol and triglycerides in mTOR versus non-mTOR inhibitor immunosuppressive treatment regimens in kidney transplant recipients. All but one of 17 trials reported higher levels of cholesterol and triglycerides, or an increased prevalence of treatment with lipid-lowering agents. Approximately 60% of mTOR inhibitor-treated patients received lipid-lowering agents (2-fold higher than controls). There appeared to be little difference between dyslipidemias caused by sirolimus (14 trials) versus everolimus (3 trials). It was difficult to determine the extent to which declines in lipids over time posttransplant were due to lipid-lowering therapy, changes in doses and/or discontinuations of mTOR inhibitors. From the four trials that measured lipoproteins, it appeared that at least some of the increase in total cholesterol with mTOR inhibitors was due to increased low-density lipoprotein cholesterol. What direct or indirect effects mTOR inhibitors have on atherosclerotic cardiovascular disease in kidney transplant patients are unknown. However, in the absence of the necessary clinical trials, dyslipidemia should be managed, as it would be in nontransplant patients at high risk for cardiovascular disease.

KW - Cardiovascular risk factors

KW - Clinical kidney transplantation

KW - Clinical trials

KW - Hypercholesterolemia

KW - Hyperlipidemia

KW - Hypertriglyceridemia

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=47249114832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249114832&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2008.02272.x

DO - 10.1111/j.1600-6143.2008.02272.x

M3 - Article

C2 - 18510633

AN - SCOPUS:47249114832

VL - 8

SP - 1384

EP - 1392

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 7

ER -